In many tapering stories there comes a moment when someone offers a cushion. We can add gabapentin, they say. It will take the edge off. And when you have been white-knuckling a benzodiazepine taper for months, that sentence can sound like rain after a drought.
Sometimes it does take the edge off. This article is not going to tell you the relief is fake. It is going to show you the whole ledger, because you deserve to read a loan agreement before you sign it.
What gabapentinoids actually are
Gabapentin, sold under the brand name Neurontin, and pregabalin, sold as Lyrica, belong to a class called gabapentinoids. Despite gabapentin’s name, it does not work on the receptors for gamma-aminobutyric acid (GABA) the way benzodiazepines do. It is thought to calm nerve signaling through a pathway of its own.
Because that pathway is different, a gabapentinoid can sometimes quiet symptoms that nothing else has touched. Some patients in benzodiazepine withdrawal report real blunting of the roar. Others notice little or nothing. As with every comfort medication, the response is individual, and no one can promise you in advance which group you will be in.
The gabapentin and pregabalin prescribing information carry cautions that matter here. Both warn of serious breathing problems when they are combined with other medicines that slow the central nervous system, benzodiazepines included, especially in people with lung or breathing problems. Both warn against stopping abruptly, and both carry a warning about new or worsening thoughts of self-harm. If those thoughts appear, call or text 988 or call emergency services.
So far, this sounds like a reasonable offer. Now for the other page of the ledger.
The loan and the bill
The nervous system adapts to gabapentinoids too. Take one regularly and the body adjusts around it, and in time it comes to depend on it to feel level. That is physical dependence. It is not addiction, and it is not a character flaw. It is the body’s ordinary accounting: what gets supplied from outside, the body stops supplying attention to on the inside.
But accounting means a bill. When the gabapentinoid is someday reduced, the body asks for repayment on its own terms: a gradual, careful gabapentin or pregabalin taper, sometimes a long one. There is a reason the Maudsley Deprescribing Guidelines, one of the core references for coming off psychiatric medications, cover gabapentinoids alongside benzodiazepines. Gabapentin dependence is an overlooked deprescribing problem in its own right, and it was overlooked long before anyone thought to use the drug as a cushion.
That is the trade in one sentence: the relief that becomes the next taper. The loan is not a perfect analogy, since nobody sets the interest rate and the repayment schedule varies from one nervous system to the next, but it captures the shape of the thing.
You came to this work to get free of one dependence. A gabapentinoid, taken to make that freedom bearable, quietly opens a second account. For some patients, in some seasons, that trade is still worth making. But it is a trade, and calling it anything softer is not honesty.
How a thoughtful physician weighs it
As a general rule, Dr. Leeds is cautious about adding a gabapentinoid in the middle of a benzodiazepine taper, precisely because stacking a new dependence on top of one being resolved can complicate the road. But there is no blanket rule here. Some medications that are commonly avoided help specific patients. The decision is made one patient at a time, by weighing this person’s suffering, this person’s history, and this person’s goals against the size of the future debt.
The questions that matter are practical. How severe are the symptoms, and are they telling us the taper itself needs to slow down first? If a gabapentinoid is added, what is the exit plan, and when does it start? If it is declined, what taper adjustments, holds, smaller cuts, steadier scheduling, can do the work instead?
Notice what is missing from that list: shame. If you are already taking gabapentin or pregabalin, whether it was added during your taper or years before it, nothing about that makes you a failure. It makes you a person whose plan has one more variable, and variables are what individualized plans are for. Sequencing, pacing, and which medication moves first are exactly the problems a physician who knows this pharmacology is there to solve with you.
Reading the whole ledger
There is a version of kindness that only tells you the comforting half. It hands you the cushion and skips the invoice. People in benzodiazepine withdrawal have usually had enough of that kind of kindness to last a lifetime.
Real respect looks different. It says: this may genuinely help you, it may cost you a second taper later, and you are intelligent enough to hold both facts and decide with your physician what your situation is worth. Borrowed relief is still relief, and debt is still debt, and the person who gets to weigh them, with the whole ledger open on the table, is you.
This article is educational. It is not medical advice, and reading it does not create a doctor-patient relationship. Decisions about starting, continuing, or tapering any medication should be made with your own physician.